Mereo BioPharma Group plc - Sponsored ADR

MREO Healthcare Biotechnology

Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.

0.30 0.01 −3.23%
Market cap
$49.3M
P/E
0.0×
Fwd P/E
−8.3×
Dividend yield
—
F-score
n/a
Altman Z
−9.11
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.71 10.46 6.48 5.88
Net Debt/EBITDA
4.62 5.37 4.21 4.39
Debt/Equity
0.01 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.05) (0.05) (0.03) (0.04)
Book value per Share
0.29 0.26 0.21 0.18
Free Cash Flow
(7.31) (7.68) (4.61) (6.04)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates